Chilton Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Chilton Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-48	Closed	-$5K	–	167
2016 Q2	$5K	Hold	48	–	–	﹤0.01%	168
2016 Q1	$5K	Hold	48	–	–	﹤0.01%	166
2015 Q4	$9K	Hold	48	–	–	﹤0.01%	153
2015 Q3	$8K	Hold	48	–	–	﹤0.01%	146
2015 Q2	$30K	Hold	48	–	–	﹤0.01%	153
2015 Q1	$25K	Hold	48	–	–	﹤0.01%	154
2014 Q4	$26K	Hold	48	–	–	﹤0.01%	163
2014 Q3	$71K	Hold	48	–	–	0.01%	156
2014 Q2	$65K	Hold	48	–	–	0.01%	161
2014 Q1	$66.1K	Hold	48	–	–	0.01%	158
2013 Q4	$47.4K	Hold	48	–	–	0.01%	259
2013 Q3	$49.6K	Hold	48	–	–	0.01%	253
2013 Q2	$52K	Buy	+48	New	+$53.5K	0.01%	257

Other funds holding VIRX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Chilton Capital Management's VIRX Position: Q3 2016 in Review

Chilton Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2016, closing a stake of 48 shares — an estimated $5K sold.

Chilton Capital Management first reported a position in VIRX in Q2 2013 and held it in 13 quarters. The position peaked at $71K in Q3 2014. 40 funds tracked by Wall St. Rank hold VIRX as of Q3 2016.

Chilton Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
Chilton Capital Management sold 48 Viracta Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $5K.
Chilton Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 13 quarters.
Chilton Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $71K in Q3 2014.
40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Chilton Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.